Reviews/Heart Failure Management/Beta-blockers reduce mortality in heart failure with reduced ejection fraction
Pharm · HFM-PHARM-03 · v2
Two randomised trials that compared a beta-blocker against a dummy pill in people with weak heart pumping found fewer deaths on the drug: one tested carvedilol [6] and the other bisoprolol [11], using different drugs in separate studies. A third randomised trial compared two beta-blockers head to head and also saw a survival difference [7]. Several large patient registries from the United States, India and Sweden tracked real-world prescribing and found lower death rates among people given a beta-blocker [2], [3], [4], and dose data pointed the same way [13]. The panel judged the evidence to point consistently in one direction, measured directly in the right patients. It also noted the signal was absent in one subgroup — patients whose heart rhythm was irregular (atrial fibrillation) [11] — and that the strongest trial enrolled people with unusually severe disease [6].
Two independent placebo-controlled randomised trials report lower all-cause mortality with beta-blockade in reduced-ejection-fraction heart failure: carvedilol showed a 35 percent decrease in the risk of death [6] and bisoprolol a relative risk of 0.58 in sinus rhythm [11]. A head-to-head randomised trial found carvedilol mortality of 34 percent versus metoprolol 40 percent (hazard ratio 0.83) [7]. Observational cohorts converge on the same direction, with a death hazard ratio of 0.85 in HFrEF [4], a 90-day mortality reduction of 4.35 percent on instrumental-variable analysis [2], and lower five-year mortality with discharge beta-blocker prescription [3]. Dose-response data show higher death or hospitalisation risk below half the recommended dose [13]. The contested point: The evidence divides on the atrial-fibrillation subgroup: [11] found no mortality benefit in atrial fibrillation (relative risk 1.16, NS) while the benefit held in sinus rhythm. The panel treated this, together with the severe-HF enrolment of [6] and the observational nature of [2], [3], [4], [13], as narrowing rather than overturning the claim.
All 13 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Heart Failure Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
[11] shows no mortality benefit in atrial fibrillation (RR 1.16, NS); the unqualified claim overreaches for that subgroup.
The supporting cohorts [2], [3], [4], [13] are observational and exposed to confounding-by-indication; [5] found BB dose not associated with all-cause mortality.
Where it remains uncertain. The bisoprolol benefit was present in sinus rhythm but not in atrial fibrillation (relative risk 1.16, NS) [11], and the carvedilol trial enrolled severe heart failure with ejection fraction below 25 percent [6].
Aleatory
Mortality reduction appeared in sinus rhythm but not atrial fibrillation in [11] (relative risk 0.58 vs 1.16), reflecting genuine heterogeneity in who benefits.
Epistemic
Direct randomised evidence rests on two 2001 trials [6], [11]; the corpus contains no recent placebo-controlled trial to confirm the effect under modern background therapy.
The load-bearing papers from a corpus of 13, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Instrumental-variable cohort showing a mortality decrease with BB in HFrEF, including patients >=75.
“receipt of a beta-blocker within 30-day of discharge was associated with a - 4.35% (95% CI - 6.27 to - 2.42%, p < 0.001) decrease in 90-day mortality”
Panel auditInternal validity: medium · scope of inference: Older Medicare HFrEF patients post-hospitalization; 90-day all-cause mortality after discharge, not long-term stable outpatient outcomes.Key limitations: post-hospitalization population, not clearly stable · 90-day horizon only · administrative claims data
Independent registry linking BB prescription to lower long-term mortality in HFrEF.
“In the multivariate Cox model, components of GDMT associated with lower 5-year mortality risks were discharge prescription of BB, RAS blocker, and MRA.”
Panel auditInternal validity: low · scope of inference: Patients admitted for acute HF in Kerala, India; speaks to discharge beta-blocker prescription and long-term mortality, confounded within a GDMT bundle.Key limitations: beta-blocker effect not isolated from GDMT bundle · no effect estimate for BB alone · acute admission cohort
Registry cohort confirming lower all-cause mortality with BB use vs non-use in HFrEF.
“Among patients with HFrEF, β-blocker use was associated with lower risk of death (adjusted hazard ratio 0.85 [95% CI, 0.75-0.96]) and cardiovascular mortality/HF hospitalization (0.87 [0.77-0.98]) compared with nonuse.”
Panel auditInternal validity: medium · scope of inference: HFrEF patients with advanced CKD (eGFR <30) in Sweden; speaks to beta-blocker and mortality in a renal-impaired HFrEF subgroup.Key limitations: observational · advanced-CKD subgroup, not general stable HFrEF · confounding by indication
The abstract reports only that beta-blocker dose was not associated with mortality; it provides no comparison of beta-blocker therapy versus none, so the claim's contrast is not addressed.
Panel auditInternal validity: low · scope of inference: HFrEF and HFpEF outpatients in Dutch cardiology clinics; speaks to beta-blocker dosing, not the presence versus absence of therapy.Key limitations: dose-response design, not therapy vs none · small sample · mixed HFrEF/HFpEF population
4 of 13 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Concordant placebo-controlled randomised mortality evidence from two agents, reinforced by independent multi-country cohorts, carries the claim to the Established tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No modern placebo-controlled RCT. The direct randomised basis is two 2001 trials [6], [11]; background therapy has changed since. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A contemporary placebo-controlled or registry-based randomised trial of beta-blockade in stable HFrEF on current guideline-directed therapy.
Open question: Does beta-blockade reduce all-cause mortality in HFrEF patients with atrial fibrillation? Why it is still open: [11] found a relative risk of 1.16 (NS) in atrial fibrillation against 0.58 in sinus rhythm, and no other corpus study resolves it.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19